ATC Group: G04BD Urinary antispasmodics

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G04BD in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G04 Urologicals
3 G04B Other urologicals, incl. antispasmodics
4 G04BD Urinary antispasmodics

Group G04BD contents

Code Title
G04BD01 Emepronium
G04BD02 Flavoxate
G04BD03 Meladrazine
G04BD04 Oxybutynin
G04BD05 Terodiline
G04BD06 Propiverine
G04BD07 Tolterodine
G04BD08 Solifenacin
G04BD09 Trospium
G04BD10 Darifenacin
G04BD11 Fesoterodine
G04BD12
G04BD13
G04BD14
G04BD15

Active ingredients in G04BD

Active Ingredient Description
Darifenacin

Darifenacin is a selective muscarinic M3 receptor antagonist (M3 SRA) in vitro. The M3 receptor is the major subtype that controls urinary bladder muscle contraction. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

Desfesoterodine

Desfesoterodine is a competitive, specific muscarinic receptor antagonist. It is the primary active metabolite of fesoterodine, and regarded as main active pharmacological principle of fesoterodine; fesoterodine is considered as prodrug of desfesoterodine. The affinity of desfesoterodine for the muscarinic receptors is 2 orders of magnitude greater than that of fesoterodine.

Fesoterodine

Fesoterodine is a competitive, specific muscarinic receptor antagonist. It is rapidly and extensively hydrolysed by non-specific plasma esterases to the 5-hydroxymethyl derivative, its primary active metabolite, which is the main active pharmacological principle of fesoterodine.

Flavoxate

Flavoxate is an antispasmodic selective to the urinary tract. Flavoxate has been shown to have a direct antispasmodic action on smooth muscle fibres.

Imidafenacin

Imidafenacin is an antagonist of muscarinic cholinergic receptors and used for treatments of overactive bladder. Imidafenacin antagonizes subtypes M3 and M1 in vitro. In the urinary bladder, imidafenacin inhibits acetylcholine release by antagonizing subtype M1 and contraction of smooth muscles by antagonizing subtype M3. Compared with the inhibitory effect on the salivary gland, imidafenacin shows higher inhibitory effect on the urinary bladder contraction, probably indicating efficacy and safety of these products in the clinical practice.

Mirabegron

Mirabegron is a potent and selective beta3-adrenoceptor agonist. Mirabegron enhances urine storage function by stimulating beta3-adrenoceptors in the bladder.

Oxybutinin

Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.

Propiverine

Propiverine inhibits calcium influx and modulates intracellular calcium in urinary bladder smooth muscle cells causing musculotropic spasmolysis. Also, it inhibits the efferent connection of the nervus pelvicus due to anticholinergic action.

Solifenacin

Solifenacin is a competitive, specific cholinergic-receptor antagonist. In vitro and in vivo pharmacological studies indicate that solifenacin is a competitive inhibitor of the muscarinic M3 subtype receptor.

Terodiline
Tolterodine

Tolterodine is a competitive, specific muscarinic receptor antagonist with selectivity for the urinary bladder over salivary glands in vivo.

Trospium

Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Receptor assays showed that trospium has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses. Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.

Vibegron

Vibegron is a selective human beta-3 adrenergic receptor agonist. Activation of the beta-3 adrenergic receptor increases bladder capacity by relaxing the detrusor smooth muscle during bladder filling.

Related product monographs

Title Information Source Document Type  
BETMIGA Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
BLADURIL Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
DETROL LA Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
DETRUNORM Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
EMSELEX Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
ENABLEX Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
GEMTESA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
KENTERA Transdermal patch European Medicines Agency (EU) MPI, EU: SmPC
LYRINEL XL Prolonged release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OXYTROL Transdermal system FDA, National Drug Code (US) MPI, US: SPL/PLR
REGURIN XL Prolonged-release capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TOLTERODINE ACCORD Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TOVEDESO Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TOVIAZ Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
URAPLEX Coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
URISPAS Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
URITOS / URITOS OD Tablet Web Search MPI, US: SPL/Old
VESICARE Oral suspension Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VEZIMED Film-coated tablet Web Search MPI, EU: SmPC